Medivir AB (publ)
MVRBF · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $1 |
| % Growth | 109.8% | 120% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $1 | $1 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $16 | $26 |
| SG&A Expenses | $0 | $0 | $16 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $16 | $23 | $33 |
| Operating Income | -$19 | -$15 | -$22 | -$32 |
| % Margin | -808.2% | -1,327.3% | -4,420% | -6,400% |
| Other Income/Exp. Net | $1 | -$0 | -$1 | -$1 |
| Pre-Tax Income | -$18 | -$15 | -$23 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$15 | -$23 | -$33 |
| % Margin | -782.7% | -1,345.5% | -4,620% | -6,540% |
| EPS | -0.32 | -0.27 | -0.41 | -0.59 |
| % Growth | -18.5% | 34.1% | 30.5% | – |
| EPS Diluted | -0.32 | -0.27 | -0.41 | -0.59 |
| Weighted Avg Shares Out | 56 | 56 | 56 | 56 |
| Weighted Avg Shares Out Dil | 56 | 56 | 56 | 56 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$18 | -$14 | -$21 | -$31 |
| % Margin | -795.8% | -1,272.7% | -4,280% | -6,280% |